Biomarkers of Sunitinib Activity in Kidney Cancer
Author Information
Author(s): Samuel E. DePrimo, Carlo L. Bello, John Smeraglia, Charles M. Baum, Dominic Spinella, Brian I. Rini, M. Dror Michaelson, Robert J. Motzer
Primary Institution: Pfizer Global Research and Development
Hypothesis
The study aims to explore potential biomarkers of sunitinib pharmacological activity in patients with metastatic renal cell carcinoma.
Conclusion
Sunitinib treatment in advanced RCC patients leads to modulation of plasma levels of circulating proteins involved in VEGF signaling, which may serve as biomarkers of the drug's activity.
Supporting Evidence
- VEGF and PlGF levels increased >3-fold in 44% and 40% of cases, respectively.
- sVEGFR-2 levels decreased by at least 30% in 91% of cases.
- sVEGFR-3 levels decreased by at least 30% in 87% of cases.
- Significantly larger changes in biomarkers were observed in patients with objective tumor response.
Takeaway
This study looked at how a cancer drug called sunitinib affects certain proteins in the blood of kidney cancer patients, helping doctors understand how well the drug works.
Methodology
Patients received sunitinib at 50 mg/day on a 4/2 schedule, with plasma samples collected and analyzed via ELISA.
Potential Biases
Potential bias due to the involvement of authors from Pfizer, the drug manufacturer.
Limitations
The study's findings may not be generalizable due to the specific patient population and the nature of the biomarkers assessed.
Participant Demographics
Median age was 60 years, with 87% having clear-cell histology.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website